Adenovirus-mediated dystrophin minigene transfer improves muscle strength in adult dystrophic (MDX) mice

Gene Therapy

Volumn 5, Issue 3, 1998, Pages 369-379

  Yang, L ^a   Lochmuller, H ^b,c   Luo, J ^a   Massie, B ^d   Nalbantoglu, J ^b   Karpati, G ^b   Petrof, B J ^a,e  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^e ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Duchenne muscular dystrophy; Immunosuppression; Mdx diaphragm; Muscle function; Viral toxicity

Indexed keywords

DYSTROPHIN;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DUCHENNE MUSCULAR DYSTROPHY; GENE TRANSFER; MOUSE; MUSCLE STRENGTH; NONHUMAN; PRIORITY JOURNAL; SARCOLEMMA; VIRUS RECOMBINANT; X CHROMOSOME LINKAGE;

ADENOVIRIDAE; ANIMALIA; DNA VIRUSES; MURINAE;

EID: 0031907287     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300600     Document Type: Article

References (39)

1. Smith PEM et al. Practical problems in the respiratory care of patients with muscular dystrophy. New Engl J Med 1987; 316: 1197-1204.
2. Khan MA. Corticosteroid therapy in Duchenne muscular dystrophy. J Neurol Sci 1993; 120: 8-14.
3. Huffman EP, Brown RHJ, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987; 51: 919-928.
4. Weller B, Karpati G, Carpenter S. Dystrophin-deficient mdx muscle fibers are preferentially vulnerable to necrosis induced by experimental lengthening contractions. J Neurol Sci 1990; 100: 9-13.
5. Petrof BJ et al. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci USA 1993; 90: 3710-3714.
6. 2+. J Physiol 1990; 420: 337-353.
7. Williams DA, Head SI, Lynch GS, Stephenson DG. Contractile properties of skinned muscle fibres from young and adult normal and dystrophic (mdx) mice. J Physiol 1993; 460: 51-67.
8. Kozarsky KF, Wilson JM. Gene therapy: adenovirus vectors. Curr Opin Genet Dev 1993; 3: 499-503.
9. Acsadi G et al. Dystrophin expression in muscles of mdx mice after adenovirus-mediated in vivo gene transfer. Hum Gene Ther 1996; 7: 129-140.
10. Lochmuller H et al. Transient immunosuppression by FK506 permits a sustained high-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscles of adult dystrophic (mdx) mice. Gene Therapy 1996; 3: 706-716.
11. Petrof BJ et al Efficiency and functional consequences of adenovirus-mediated in vivo gene transfer to normal and dystrophic (mdx) mouse diaphragm. Am J Resp Cell Mol Biol 1995; 13: 508-517.
12. + T cell deficiency. Hum Gene Ther 1996; 7: 1813-1826.
13. Karpati G, Carpenter S, Prescott S. Small-caliber skeletal muscle fibers do not suffer necrosis in mdx mouse dystrophy. Muscle Nerve 1988; 11: 795-803.
14. Phelps SF et al. Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Hum Mol Genet 1995; 4: 1251-1258.
15. Wells DJ et al. Expression of human full-length and minidystrophin in transgenic mdx mice: implications for gene therapy of Duchenne muscular dystrophy. Hum Mol Genet 1995; 4: 12451250.
16. Stedman HH el al. The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature 1991; 352: 536-539.
17. Moscovici C, Maisel J. A toxin-like material separable from type 5 adenovirus particles. Virology 1958; 6: 770-771.
18. Seth P et al. Evidence that the penton base of adenovirus is involved in potentiation of toxicity of pseudomonas exotoxin conjugated to epidermal growth factor. Mol Cell Biol 1984; 4: 1528-1533.
19. Yang Y et al. Cellular immunity to viral antigens limits Eldeleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407-4411.
20. Yang Y et al. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet 1994; 7: 362-369.
21. Dai Y et al. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 1995; 92: 1401-1405.
22. McCoy RD et al. Pulmonary inflammation induced by incomplete or inactivated adenoviral particles. Hum Gene Ther 1995; 6: 1533-1560.
23. Brynes AP, Rusby JE, Wood MJA, Charlton HM. Adenovirus gene transfer causes inflammation in the brain. Neuroscience 1995; 66: 1015-1024.
24. Spergel JM et al. NF-IL6, a member of the C/EBP family, regulates ElA-responsive promoters in the absence of ElA. J Virol 1992; 66: 1021-1030.
25. Ragot T et al. Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice. Nature 1993; 361: 647-650.
26. Vincent N et al. Long-term correction of mouse dystrophic degeneration by adenovirus-mediated transfer of a minidystrophin gene. Nat Genet 1993; 5: 130-134.
27. Deconinck N et al. Functional protection of dystrophic mouse (mdx) muscles after adenovirus-mediated transfer of a dystrophin minigene- Proc Natl Acad Sci USA 1996; 93: 3570-3574.
28. Weller B et al. Inhibition of myosatellite cell proliferation by gamma irradiation does not prevent the age-related increase of the number of dystrophin-positive fibers in soleus muscles of mdx female heterozygote mice. Am J Pathol 1991; 138:1497-1502.
29. Petrof BJ et al. Adaptations in myosin heavy chain expression and contractile function in the dystrophic (MDX) mouse diaphragm. Am J Physiol 1993; 265: C834-C841.
30. c4 diaphragm muscle fibers increases sarcolemmal stability. Gene Therapy 1997; 4: 401-408.
31. Sharma KR, Mynhier MA, Miller RG. Cyclosporine increases muscular force generation in Duchenne muscular dystrophy. Neurology 1993; 43: 527-532.
32. Halbert DN, Cutt JR, Shenk T. Adenovirus early region 4 encodes functions required for efficient DNA replication, late gene expression, and host cell shutoff. J Virol 1985; 56: 250-257.
33. Dobner T, Horikoshi N, Rubenwolf S, Shenk T. Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor. Science 1996; 272: 1470-1473.
34. Gao G-P, Yang Y, Wilson JM. Biology of adenovirus vectors with El and E4 deletions for liver-directed gene therapy. J Virol 1996; 70: 8934-8943.
35. Kochanek S et al. A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and β-galactosidase. Proc Natl Acad Sci USA 1996; 93: 5731-5736.
36. Haecker SE et al. In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes. Hum Gene Ther 1996; 7: 1907-1914.
37. Huard J et al. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Therapy 1995; 2: 107-115.
38. England SB et al. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 1990; 343: 180-182.
39. Lochmuller H et al. Emergence of early region 1-containing replication-competent adenovirus in stocks of replication-defective adenovirus recombinants during multiple passsages in 293 cells. Hum Gene Ther 1994; 5: 1485-1491.